Figure 6. Dose escalation in immunocompetent and immunocompromised myeloma tumor models validates model predictions.

(A) Tumor volume monitored by serial caliper measurements in C57Bl6/KaLwRij mice bearing 5TGM1 tumors after single IV administration of sterile saline or VSV-mIFNβ-NIS at doses of 10⁵, 10⁶, 10⁷, or 10⁸ TCID₅₀ (top) and in CB17 ICR SCID mice bearing KAS 6/1 tumors after single IV administration of sterile saline or VSV-mIFNβ-NIS at doses of 10⁵, 10⁶, 10⁷, or 10⁸ TCID₅₀ (bottom) is plotted against time. Dotted line represents tumor volume sacrifice criteria. Dose escalation is used to model increasing K. Immunocompromised mice allow for extended periods of infectious foci expansion, increasing r/R. The model is validated by (B) dose-dependent tumor response, defined as proportion of mice with tumor regression at day 12 relative to baseline, and (C) partial remission, defined as tumor regression ≥50% compared to baseline after a single IV injection of VSV-IFNß-NIS in immunocompetent C57Bl6/KaLwRij or immunocompromised SCID mice bearing subcutaneous plasmacytomas.